These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Treatment of Heart Failure with Preserved Ejection Fraction. Ilieșiu AM; Hodorogea AS Adv Exp Med Biol; 2018; 1067():67-87. PubMed ID: 29498023 [TBL] [Abstract][Full Text] [Related]
10. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. Tromp J; Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Køber L; Swedberg K; Zile MR; Pitt B; Lam CSP; McMurray JJV J Am Coll Cardiol; 2019 Aug; 74(5):601-612. PubMed ID: 31370950 [TBL] [Abstract][Full Text] [Related]
11. Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions. Peters AE; Tromp J; Shah SJ; Lam CSP; Lewis GD; Borlaug BA; Sharma K; Pandey A; Sweitzer NK; Kitzman DW; Mentz RJ Cardiovasc Res; 2023 Feb; 118(18):3403-3415. PubMed ID: 36448685 [TBL] [Abstract][Full Text] [Related]
12. Current therapeutic approach in heart failure with preserved ejection fraction. Nativi-Nicolau J; Ryan JJ; Fang JC Heart Fail Clin; 2014 Jul; 10(3):525-38. PubMed ID: 24975914 [TBL] [Abstract][Full Text] [Related]
13. Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study. Kontogeorgos S; Thunström E; Johansson MC; Fu M Int J Cardiol; 2017 Apr; 232():86-92. PubMed ID: 28100428 [TBL] [Abstract][Full Text] [Related]
14. Phenomapping Heart Failure with Preserved Ejection Fraction Using Machine Learning Cluster Analysis: Prognostic and Therapeutic Implications. Galli E; Bourg C; Kosmala W; Oger E; Donal E Heart Fail Clin; 2021 Jul; 17(3):499-518. PubMed ID: 34051979 [TBL] [Abstract][Full Text] [Related]
15. Heart failure with preserved ejection fraction: emerging drug strategies. Zouein FA; de Castro Brás LE; da Costa DV; Lindsey ML; Kurdi M; Booz GW J Cardiovasc Pharmacol; 2013 Jul; 62(1):13-21. PubMed ID: 23714774 [TBL] [Abstract][Full Text] [Related]
17. Assessing the Eligibility Criteria in Phase III Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection Fraction: The Critical Play-Off Between a "Pure" Patient Phenotype and the Generalizability of Trial Findings. Patel HC; Hayward C; Dungu JN; Papadopoulou S; Saidmeerasah A; Ray R; Di Mario C; Shanmugam N; Cowie MR; Anderson LJ J Card Fail; 2017 Jul; 23(7):517-524. PubMed ID: 28434933 [TBL] [Abstract][Full Text] [Related]
18. The future of heart failure with preserved ejection fraction : Deep phenotyping for targeted therapeutics. Heinzel FR; Shah SJ Herz; 2022 Aug; 47(4):308-323. PubMed ID: 35767073 [TBL] [Abstract][Full Text] [Related]
19. Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. Dixon DD; Trivedi A; Shah SJ Heart Fail Rev; 2016 May; 21(3):285-97. PubMed ID: 26714826 [TBL] [Abstract][Full Text] [Related]
20. Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment. Xanthopoulos A; Triposkiadis F; Starling RC Trends Cardiovasc Med; 2018 Aug; 28(6):392-400. PubMed ID: 29471985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]